Grifols (NASDAQ:GRFS) Trading Down 3.7% – Should You Sell?

Grifols, S.A. (NASDAQ:GRFS)’s share price traded down 3.7% during trading on Friday . The company traded as low as $7.16 and last traded at $7.20. 616,128 shares were traded during mid-day trading, a decline of 10% from the average session volume of 683,670 shares. The stock had previously closed at $7.47.

Wall Street Analysts Forecast Growth

Separately, Berenberg Bank upgraded Grifols to a “strong-buy” rating in a research note on Tuesday, October 29th.

Grifols Stock Performance

The firm has a market cap of $5.05 billion, a price-to-earnings ratio of 6.13 and a beta of 0.41. The firm’s 50 day moving average price is $7.66 and its 200-day moving average price is $8.19. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. R Squared Ltd acquired a new stake in Grifols during the fourth quarter worth about $28,000. GAMMA Investing LLC grew its holdings in shares of Grifols by 49.4% during the 3rd quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 1,135 shares in the last quarter. Signaturefd LLC raised its stake in shares of Grifols by 66.2% in the third quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 2,153 shares in the last quarter. Blue Trust Inc. raised its stake in shares of Grifols by 254.0% in the fourth quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 4,970 shares in the last quarter. Finally, AQR Capital Management LLC bought a new position in Grifols in the second quarter worth $89,000.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.